ImmunityBio Faces Class Action Lawsuit Over Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Should l Buy IBRX?
Source: Globenewswire
ImmunityBio Inc's stock price fell by 7.69% as it crossed below the 5-day SMA, reflecting investor concerns following recent legal developments.
The company is facing a class action lawsuit initiated by Bronstein, Gewirtz & Grossman, LLC, which alleges that CEO Soon-Shiong made materially false statements about the capabilities of Anktiva, leading to significant investor losses. The lawsuit highlights the risks for investors who purchased shares between January 19 and March 24, 2026, and provides an opportunity for them to seek damages. Additionally, the FDA issued a warning letter regarding misleading claims about Anktiva, further impacting investor confidence and the company's reputation.
These legal challenges could have serious implications for ImmunityBio, as they not only threaten financial recovery for affected investors but also raise questions about the company's future prospects and compliance with federal securities laws.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.120
Low
5.00
Averages
7.33
High
9.00
Current: 8.120
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statements Allegation: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant transparency issues within the company.
- Investor Rights Protection: The Schall Law Firm encourages shareholders who suffered losses during the class period to contact them before May 26, 2026, to participate in the lawsuit and seek compensation, emphasizing the importance of protecting investor rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, warning shareholders that failing to act may result in being an absent class member, underscoring the complexities of legal proceedings.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: ImmunityBio, Inc. (NASDAQ: IBRX) is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934 during the period from January 19 to March 24, 2026, with investors having until May 26, 2026, to seek lead plaintiff status, highlighting significant legal risks for the company.
- False Statement Allegations: The lawsuit accuses ImmunityBio and its Executive Chairman of making false and misleading statements regarding the efficacy of its lead biologic product, Anktiva, which could undermine investor confidence in the company's future prospects.
- FDA Warning Impact: A warning letter from the FDA, publicized on March 24, 2026, indicated that Anktiva's advertising was misleading, resulting in a 21% drop in ImmunityBio's stock price, reflecting the stringent scrutiny from regulators that may affect the company's market performance.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, demonstrating its strong capabilities and influence in handling such cases.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm will operate on a contingency fee basis, ensuring legal support without financial burden for the investors.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the truth was revealed, highlighting serious misrepresentations regarding the company's operations and prospects.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its expertise and successful track record in this field.
See More
ImmunityBio Investors Reminder for Class Action Filing
- Lawsuit Background: ImmunityBio received a warning from the FDA due to false claims made by Executive Chairman Soon-Shiong regarding Anktiva, resulting in a 21.12% stock price drop to $7.42 on March 24, 2026, highlighting the company's legal risks and market trust issues.
- Class Action Details: Investors are reminded to file a lead plaintiff motion by May 26, 2026, alleging that the company made misleading statements from January 19 to March 24, 2026, failing to disclose the true capabilities of Anktiva, which may have led to misjudgments about the company's prospects.
- Legal Consequences: The lawsuit claims that executives intentionally overstated Anktiva's efficacy, resulting in investors lacking accurate information when purchasing securities, potentially leading to liability and further impacting the company's reputation and shareholder confidence.
- Investor Action Advice: Affected investors can contact Glancy Prongay Wolke & Rotter LLP to participate in the lawsuit and seek legal support to recover losses, emphasizing the importance of protecting investor rights under federal securities laws.
See More
ImmunityBio Investors Reminder for Class Action Lawsuit
- Lawsuit Deadline: Investors must file Lead Plaintiff applications by May 26, 2026, for those who purchased ImmunityBio securities between January 19 and March 24, 2026, highlighting the urgency and significance of this case.
- FDA Warning Impact: Following a March 13, 2026 FDA warning letter accusing ImmunityBio of misleading advertising for Anktiva, the company's stock plummeted 21% on March 24, 2026, falling $1.98 to close at $7.42, illustrating the direct impact of regulatory risks on stock performance.
- Legal Liability Allegations: ImmunityBio and its executives are charged with failing to disclose material information during the class period, violating federal securities laws, indicating serious deficiencies in the company's transparency that could undermine investor confidence.
- Legal Support Channels: Investors can contact KSF law firm to discuss their legal rights, indicating the firm's commitment to supporting affected investors and enhancing their confidence in seeking legal remedies.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, potentially leading to investor losses.
- Stock Price Plunge: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations and operating on a contingency fee basis.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading U.S. law firm specializing in securities fraud class actions, having recovered over $25 billion for clients, showcasing its significant expertise and influence in the securities litigation landscape.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statements Allegation: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant transparency issues within the company.
- Investor Rights Protection: The Schall Law Firm encourages shareholders who suffered losses during the class period to contact them before May 26, 2026, to participate in the lawsuit and seek compensation, emphasizing the importance of protecting investor rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, warning shareholders that failing to act may result in being an absent class member, underscoring the complexities of legal proceedings.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: ImmunityBio, Inc. (NASDAQ: IBRX) is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934 during the period from January 19 to March 24, 2026, with investors having until May 26, 2026, to seek lead plaintiff status, highlighting significant legal risks for the company.
- False Statement Allegations: The lawsuit accuses ImmunityBio and its Executive Chairman of making false and misleading statements regarding the efficacy of its lead biologic product, Anktiva, which could undermine investor confidence in the company's future prospects.
- FDA Warning Impact: A warning letter from the FDA, publicized on March 24, 2026, indicated that Anktiva's advertising was misleading, resulting in a 21% drop in ImmunityBio's stock price, reflecting the stringent scrutiny from regulators that may affect the company's market performance.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, demonstrating its strong capabilities and influence in handling such cases.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm will operate on a contingency fee basis, ensuring legal support without financial burden for the investors.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the truth was revealed, highlighting serious misrepresentations regarding the company's operations and prospects.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its expertise and successful track record in this field.
See More
ImmunityBio Investors Reminder for Class Action Filing
- Lawsuit Background: ImmunityBio received a warning from the FDA due to false claims made by Executive Chairman Soon-Shiong regarding Anktiva, resulting in a 21.12% stock price drop to $7.42 on March 24, 2026, highlighting the company's legal risks and market trust issues.
- Class Action Details: Investors are reminded to file a lead plaintiff motion by May 26, 2026, alleging that the company made misleading statements from January 19 to March 24, 2026, failing to disclose the true capabilities of Anktiva, which may have led to misjudgments about the company's prospects.
- Legal Consequences: The lawsuit claims that executives intentionally overstated Anktiva's efficacy, resulting in investors lacking accurate information when purchasing securities, potentially leading to liability and further impacting the company's reputation and shareholder confidence.
- Investor Action Advice: Affected investors can contact Glancy Prongay Wolke & Rotter LLP to participate in the lawsuit and seek legal support to recover losses, emphasizing the importance of protecting investor rights under federal securities laws.
See More
ImmunityBio Investors Reminder for Class Action Lawsuit
- Lawsuit Deadline: Investors must file Lead Plaintiff applications by May 26, 2026, for those who purchased ImmunityBio securities between January 19 and March 24, 2026, highlighting the urgency and significance of this case.
- FDA Warning Impact: Following a March 13, 2026 FDA warning letter accusing ImmunityBio of misleading advertising for Anktiva, the company's stock plummeted 21% on March 24, 2026, falling $1.98 to close at $7.42, illustrating the direct impact of regulatory risks on stock performance.
- Legal Liability Allegations: ImmunityBio and its executives are charged with failing to disclose material information during the class period, violating federal securities laws, indicating serious deficiencies in the company's transparency that could undermine investor confidence.
- Legal Support Channels: Investors can contact KSF law firm to discuss their legal rights, indicating the firm's commitment to supporting affected investors and enhancing their confidence in seeking legal remedies.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, potentially leading to investor losses.
- Stock Price Plunge: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations and operating on a contingency fee basis.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading U.S. law firm specializing in securities fraud class actions, having recovered over $25 billion for clients, showcasing its significant expertise and influence in the securities litigation landscape.
See More
